Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality

1 Escárcega RO  García-Carrasco M  Fuentes-Alexandro S  . Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev 2006; 6: 48–53.

2 Doria A  Iaccarino L  Sarzi-Puttini P  Atzeni F  Turriel M  Petri M  . Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14: 683–686.

3 Manzi S  Meilahn EN  Rairie JE  . Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408–415.

4 Cervera R  Khamashta MA  Font J  . Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999; 78: 167–175.

5 Esdaile JM  Abrahamowicz M  Grodzicky T  . Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331–2337.

6 García-Carrasco M  Escárcega RO  Pérez-Terrón J  . Lack of subclinical myocardial ischaemia in Mexican patients with systemic lupus erythematosus without traditional risk factors for coronary artery disease. Lupus 2007; 16: 298–301.

7 Kinlay S  Selwyn AP  Delagrange D  Creager MA  Libby P  Ganz P  . Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol 1996; 7: 389–397.

8 Kastelein JJ  Akdim F  Stroes ES  . ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431–1443.

9 Brown GB  Taylor AJ  . Does ENHANCE diminish confidence in lowering LDL or in Ezetimibe. N Engl J Med 2008; 358: 1504–1506.

10 Jackevicius CA  Tu JV  Ross JS  Ko D  Krumholz H  . Use of ezetimibe in the United States and Canada. N Engl J Med 2008; 358: 1819–1828.

11 Tinetti ME  . Over-the-counter sales of statins and other drugs for asymptomatic conditions. N Engl J Med 2008; 358: 2728–2732.

12 Petri M  Kiani A  Post W  Madger L  . Lupus Atherosclerosis prevention study (LAPS): a randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum; 54(Suppl.): S5–S20.

13 Lawman S  Mauri C  Jury EC  Cook HT  Ehrestein MR  . Atorvastatin Inhibit autoreactive B cell activation and delays lupus development in new Zealand black/white F1 mice. J Immunol 2004; 173: 7641–7646.

14 Petri M  Spence D  Bone LR  Hochberg MC  . Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients and preventive practices. Medicine 1992; 71: 291–302.

15 Bruce IN  Urowitz MB  Gladman DD  Ibañez D  Steiner G  . Risk factors for coronary heart disease in women with systemic lupus erythematosus (The Toronto risk factor study). Arthritis Rheum 2003; 48: 3159–3167.

16 Petri M  Rubenhoff R  Dallal GE  Nadeau MR  Selhub J  Rosenberg IH  . Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120–1124.

17 Van den Brandhof WE  Haks K  Schouten EG  Verhoef P  . The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis 2001; 157: 403–409.

18 Sherer Y  Tenembaum A  Praprotnik S  . Coronary disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology 2001; 95: 20–24.

19 Sherer Y  Shoenfeld Y  . Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006; 2: 99–106.

20 Colombo BM  Cacciapaglia F  Puntoni M  . Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS study). Autoimmun Rev 2008; DOI: 10.1016/j.autrev.2008.10.002.

21 Eidelman RS  Hebert PR  Weisman SE  Hennekens CH  . An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 2003; 163: 2006–2010.

22 Ridker PM  Cook NR  Lee IM  . A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Eng J Med 2005; 352: 1293–1304.